UY26167A1 - Hidroxiamidas de acidos 3 (arilsulfonilamino) tetrahidropiran-3-carboxilicos. - Google Patents

Hidroxiamidas de acidos 3 (arilsulfonilamino) tetrahidropiran-3-carboxilicos.

Info

Publication number
UY26167A1
UY26167A1 UY26167A UY26167A UY26167A1 UY 26167 A1 UY26167 A1 UY 26167A1 UY 26167 A UY26167 A UY 26167A UY 26167 A UY26167 A UY 26167A UY 26167 A1 UY26167 A1 UY 26167A1
Authority
UY
Uruguay
Prior art keywords
hydroxiamides
tetrahydropiran
arylsulfonylamine
carboxylics
acid
Prior art date
Application number
UY26167A
Other languages
English (en)
Inventor
Lawrence Alan Reiter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26167A1 publication Critical patent/UY26167A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Abstract

Un compuesto de fórmula en la que R1, R2, R3 y Q son como se han definido antes, que es útil en el tratamiento de la artritis (incluyendo osteoartritis y artritis reumatoide), el cáncer y otras enfermedades. Además, los compuestos de la presente invención se pueden usar en terapia de combinación con fármacos antiinflamatorios no esteroideos (AiNE), inhibidores de la COX-2 y analgésicos convencionales, y en combinación con fármacos citotóxicos como adriamicina, daunomicina, cisplatino, etopósido, taxol, taxótero y otros alcaloides, como vincristina, en el tratamiento del cáncer.
UY26167A 1999-05-28 2000-05-26 Hidroxiamidas de acidos 3 (arilsulfonilamino) tetrahidropiran-3-carboxilicos. UY26167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13653099P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
UY26167A1 true UY26167A1 (es) 2000-12-29

Family

ID=22473239

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26167A UY26167A1 (es) 1999-05-28 2000-05-26 Hidroxiamidas de acidos 3 (arilsulfonilamino) tetrahidropiran-3-carboxilicos.

Country Status (22)

Country Link
US (1) US6197810B1 (es)
EP (1) EP1181286B1 (es)
JP (1) JP3784645B2 (es)
AT (1) ATE254119T1 (es)
AU (1) AU4424000A (es)
BR (1) BR0011539A (es)
CA (1) CA2375524C (es)
DE (1) DE60006523T2 (es)
DK (1) DK1181286T3 (es)
DZ (1) DZ3046A1 (es)
ES (1) ES2208315T3 (es)
GT (1) GT200000079A (es)
HN (1) HN2000000074A (es)
MA (1) MA26738A1 (es)
MX (1) MXPA01012265A (es)
PA (1) PA8495901A1 (es)
PE (1) PE20010170A1 (es)
PT (1) PT1181286E (es)
SV (1) SV2001000086A (es)
TN (1) TNSN00111A1 (es)
UY (1) UY26167A1 (es)
WO (1) WO2000073295A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
WO2001070691A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
IL151124A0 (en) * 2000-03-21 2003-04-10 Procter & Gamble Heterocyclic side chain containing metalloprotease inhibitors
AU2001245862A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
US7019376B2 (en) * 2000-08-11 2006-03-28 Reflectivity, Inc Micromirror array device with a small pitch size
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
US20050058611A1 (en) * 2003-08-22 2005-03-17 L'oreal Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
WO2010079443A1 (en) * 2009-01-12 2010-07-15 Pfizer Limited Sulfonamide derivatives
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
PL335027A1 (en) 1997-02-03 2000-03-27 Pfizer Prod Inc Derivatives of arylsulphonylamino hydroxamic acid
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico

Also Published As

Publication number Publication date
CA2375524C (en) 2006-11-28
PA8495901A1 (es) 2002-08-26
BR0011539A (pt) 2002-02-26
TNSN00111A1 (fr) 2002-05-30
MA26738A1 (fr) 2004-12-20
JP2003500485A (ja) 2003-01-07
DE60006523D1 (de) 2003-12-18
MXPA01012265A (es) 2002-07-30
EP1181286B1 (en) 2003-11-12
PT1181286E (pt) 2004-02-27
HN2000000074A (es) 2001-02-02
EP1181286A1 (en) 2002-02-27
JP3784645B2 (ja) 2006-06-14
ES2208315T3 (es) 2004-06-16
GT200000079A (es) 2001-11-16
US6197810B1 (en) 2001-03-06
ATE254119T1 (de) 2003-11-15
SV2001000086A (es) 2001-11-08
AU4424000A (en) 2000-12-18
WO2000073295A1 (en) 2000-12-07
DE60006523T2 (de) 2004-08-12
DZ3046A1 (fr) 2004-03-27
CA2375524A1 (en) 2000-12-07
PE20010170A1 (es) 2001-02-27
DK1181286T3 (da) 2004-02-16

Similar Documents

Publication Publication Date Title
GT199900132A (es) Inhibidores de tace.
YU5201A (sh) Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
AP9801174A0 (en) Cyclic sulfone derivatives.
TR200002951T2 (tr) (4-Arilsülfonilamino)-tetrahidropiran-4-karboksilik asit hidroksamitler
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
YU37499A (sh) Derivati arilsulfonil hidroksamske kiseline
CA2260898A1 (en) Phosphinate based inhibitors of matrix metalloproteases
UY26167A1 (es) Hidroxiamidas de acidos 3 (arilsulfonilamino) tetrahidropiran-3-carboxilicos.
UY26169A1 (es) Hidroxiamidas de ácidos 3-(arilsulfonilamino)- tetrahidrofuran-3-carboxílicos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101201